GENSCRIPT BIO(01548): The legendary potential "First in Class" intracellular CD19/CD20 dual-target CAR-T therapy LB2501 has obtained clinical conceptual validation in relapsed/refractory B-cell Non-Hodgkin's lymphoma.

GENSCRIPT BIO (01548) announced that its joint venture company Legend Biotech Corporation (Legend, whose shares are listed on the Nasdaq Global Select Market in the form of American Depositary Shares) released a press release on June 14, 2026 (New York time), announcing the first clinical concept verification data of its investigational in vivo CD19/CD20 dual-target CAR-T cell therapy LB2501 for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/RB-NHL). The study results were presented today at the latest breakthrough session at the 2026 European Hematology Association (EHA) annual meeting (Abstract Number: LB5006). In this ongoing Phase I study, a single dose of LB2501 achieved dose-dependent expansion of CAR-T cells in vivo without the need for lymphodepletion. At the higher dose level (DL2), LB2501 achieved a 100% objective response rate (ORR) (6/6) and an 83.3% complete response rate (CR) (5/6), with all responses still ongoing at data cutoff. LB2501 also demonstrated favorable safety profiles, with no reported dose-limiting toxicities (DLT), severe adverse events (SAE), immune effector cell-associated neurotoxicity syndrome (ICANS), or death events.